Treatment of advanced hepatocellular carcinoma with long-acting octreotide: A phase III multicentre, randomised, double blind placebo-controlled study
- 1 July 2009
- journal article
- research article
- Published by Elsevier in European Journal Of Cancer
- Vol. 45 (10) , 1788-1797
- https://doi.org/10.1016/j.ejca.2009.02.018
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Long-acting octreotide versus placebo for treatment of advanced HCC: A randomized controlled double-blind studyHepatology, 2007
- A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinomaHepatology, 2002
- Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinomaHepatology, 2002
- Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL ConferenceJournal of Hepatology, 2001
- Somatostatin receptor imaging, therapy and new strategies in patients with neuroendocrine tumoursBritish Journal of Surgery, 2001
- Prospective validation of the CLIP score: A new prognostic system for patients with cirrhosis and hepatocellular carcinomaHepatology, 2000
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Epidemiology of Primary Liver CancerSeminars in Liver Disease, 1999
- OctreotideNew England Journal of Medicine, 1996